- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07589400
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B
A Multicenter, Randomized, Double-blind, Multiple Ascending Dose, Placebo-controlled Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-associated Steatotic Liver Disease Complicated With Chronic Hepatitis B.
A tanulmány áttekintése
Állapot
Beavatkozás / kezelés
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- 1. fázis
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: Jidong Jia, Ph.D
- Telefonszám: 13501378269
- E-mail: jia_jd@ccmu.edu.cn
Tanulmányi helyek
-
-
-
Beijing, Kína
- Beijing Friendship hospital, Capital Medical University
-
Kapcsolatba lépni:
- Jidong Jia
- Telefonszám: 13501378269
- E-mail: jia_jd@ccmu.edu.cn
-
Shanghai, Kína
- Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
-
Kapcsolatba lépni:
- Qing Xie
-
Xiamen, Kína
- Xiamen Hospital of Traditional Chinese Medicine
-
Kapcsolatba lépni:
- Huiqing Liang
-
Ürümqi, Kína
- The First Affiliated Hospital of Xinjiang Medical University
-
Kapcsolatba lépni:
- Xiaobo Lu
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
- Felnőtt
Egészséges önkénteseket fogad
Leírás
Inclusion Criteria:
- The participant fully understands the purpose, nature, methods of the trial, and the potential adverse reactions, voluntarily agrees to participate in this study, and signs the informed consent form.
- Male or female participants aged between 18 and 60 years (inclusive) at the time of signing the informed consent form.
- Liver fat content ≥10% as assessed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) during the screening period.
- Liver stiffness measurement (LSM) by FibroScan during the screening period meets 8 kPa ≤ LSM < 12 kPa, or liver biopsy results within 6 months prior to screening show stage F2/F3 liver fibrosis.
- Hepatitis B surface antigen (HBsAg) positive for >6 months at screening, or other evidence of chronic hepatitis B (CHB), with HBV DNA < 20 IU/mL.
- Serum alanine aminotransferase (ALT) < 5×ULN at screening.
- Received nucleos(t)ide analog (NAs) therapy for at least 1 year prior to screening and are currently on stable NA therapy (including entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide fumarate, and tenofovir amibufenamide). Stable NAs therapy is defined as receiving the same treatment regimen within 3 months prior to screening.
- Have at least one of the following metabolic disease risk factors:
BMI ≥24.0 kg/m^2, or waist circumference ≥90 cm (male) and ≥85 cm (female); Prediabetes: fasting blood glucose ≥6.1 mmol/L, or glycated hemoglobin (HbA1c) ≥5.7%; History of type 2 diabetes mellitus; 1.70 mmol/L ≤ fasting serum triglycerides < 5.6 mmol/L; Fasting serum high-density lipoprotein cholesterol ≤1.0 mmol/L (male) and ≤1.3 mmol/L (female), or receiving stable-dose lipid-lowering therapy(excluding statins); Systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg, with systolic blood pressure ≤160 mmHg and diastolic blood pressure ≤100 mmHg; or receiving stable-dose antihypertensive therapy with systolic blood pressure ≤160 mmHg and diastolic blood pressure ≤100 mmHg.
- Both male and female participants must agree to use adequate contraceptive methods, where:
Male participants: agree to use reliable contraceptive measures from the time of signing the informed consent form until 1 months after the last dose, and have no sperm donation plans; Female participants: women of non-childbearing potential; or women of childbearing potential who are not pregnant or breastfeeding, must have a negative serum pregnancy test result at screening and within 1 day prior to the first dose, agree to use reliable contraceptive measures from the time of signing the informed consent form until 1 months after the last dose, and have no oocyte donation plans.
Exclusion Criteria:
- Concurrent other liver diseases, including but not limited to hepatitis C, hepatitis D, drug-induced liver disease, alcoholic liver disease, autoimmune liver disease, suspected or confirmed liver cancer, etc.
- Participants with a previous or current history of other malignant tumors, liver cirrhosis (including imaging-confirmed or suspected cirrhosis, and liver biopsy-confirmed cirrhosis), or evidence of decompensated liver disease (such as ascites, esophagogastric variceal bleeding, hepatic encephalopathy), or with a history of liver transplantation.
- Participants with a history or current symptoms of severe cardiovascular and cerebrovascular diseases, including but not limited to uncontrolled or severe arrhythmia (ventricular fibrillation, atrial fibrillation, etc.), myocardial infarction, coronary heart disease, uncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg).
- Participants with persistent and clinically significant medical history of respiratory, nervous, gastrointestinal, immune, hematological or psychiatric diseases, which, in the opinion of the investigator, may impose additional risks on the participant.
- Participants with type 1 diabetes or poorly controlled type 2 diabetes (fasting blood glucose >9 mmol/L within 3 months prior to screening or glycated hemoglobin >9.5% at screening), or diabetic patients using hypoglycemic drugs other than metformin and insulin.
- Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m² (calculated by the CKD-EPI formula) at screening, or with a history of severe renal impairment.
- Known hemoglobinopathy, hemolytic anemia, sickle cell anemia; or hemoglobin <115 g/L in female participants and <130 g/L in male participants at screening; or any other conditions judged by the investigator to interfere with hemoglobin detection.
- Any of the following laboratory abnormalities at screening: alkaline phosphatase (ALP) >2 times the upper limit of normal (ULN), total bilirubin (TBIL) >1.5 times the ULN(excluding participants with benign unconjugated hyperbilirubinemia who are deemed eligible for enrollment by the Investigator, with total bilirubin <2×ULN and direct bilirubin <ULN);, international normalized ratio (INR) >1.3, albumin <35 g/L, platelet count <125×10⁹/L, and serum triglycerides >5.6 mmol/L.
- Participants with body weight gain or loss >5% within 3 months prior to screening, or those receiving diet control, bariatric surgery, or using approved anti-obesity medications for weight loss indications.
- Participants with a history of major trauma or surgery within 3 months prior to screening, or those scheduled to undergo surgery during the study period.
- Excessive alcohol consumption for 3 consecutive months or more within 1 year prior to screening. Excessive drinking is defined as weekly ethanol intake ≥210 g for males and ≥140 g for females; or with a history of drug abuse/dependence or drug inhalation/injection within 1 year prior to screening.
- Use of drugs with potential therapeutic effects on MASLD/MASH within 3 months prior to screening (e.g., GLP-1 receptor agonists, DPP4 inhibitors, SGLT2 inhibitors, FGF21 analogues, resmetirom, etc.), or drugs that may induce MASLD/MASH (e.g., amiodarone, methotrexate, tetracyclines, tamoxifen, estrogen at doses exceeding hormone replacement therapy, anabolic steroids, valproic acid, and other known hepatotoxic drugs); use of drugs that may affect the efficacy of hepatitis B treatment within 6 months prior to screening (e.g., anti-HBV drugs other than NAs, interferons, systemic immunomodulators, hepatitis B vaccines, etc.), or any other medications deemed by the investigator to interfere with the study.
- Participation in other clinical drug trials within 6 months prior to screening.
- Positive human immunodeficiency virus antibody (HIV-Ab) at screening; positive hepatitis C virus antibody (if positive, HCV-RNA must be below the lower limit of quantitation of the study site assay); positive hepatitis D virus antibody; or positive treponema pallidum antibody together with positive rapid plasma reagin (RPR) test (RPR shall only be performed when treponema pallidum antibody is positive).
- Participants with allergic reactions to excipients of ACT500 or drugs with similar chemical structures to ACT500, or other drug allergies deemed ineligible for study participation by the investigator.
- Any other conditions that render the participant unsuitable for this study as determined by the investigator, or participants who are unable to complete the trial due to personal reasons after signing the informed consent form (ICF).
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Egyéb
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Négyszeres
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: 300 mg ACT500 tabletta csoport
|
Once daily, orally
|
|
Kísérleti: 400 mg ACT500 tabletta csoport
|
Once daily, orally
|
|
Kísérleti: 100 mg ACT500 tablet group
|
Once daily, orally
|
|
Placebo Comparator: 100 mg ACT500 Placebo tablet group
|
Once daily, orally
|
|
Placebo Comparator: 300 mg ACT500 Placebo tablet group
|
Once daily, orally
|
|
Placebo Comparator: 400 mg ACT500 Placebo tablet group
|
Once daily, orally
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Időkeret |
|---|---|
|
Súlyos mellékhatás
Időkeret: 1-112. nap
|
1-112. nap
|
|
Adverse Event
Időkeret: Day1-112
|
Day1-112
|
|
body temperature
Időkeret: Day1,14,29,56,84,112
|
Day1,14,29,56,84,112
|
|
breathe
Időkeret: Day1,14,29,56,84,112
|
Day1,14,29,56,84,112
|
|
pulse
Időkeret: Day1,14,29,56,84,112
|
Day1,14,29,56,84,112
|
|
blood pressure
Időkeret: Day1,14,29,56,84,112
|
Day1,14,29,56,84,112
|
|
Number of Participants with Abnormal Laboratory Parameters Findings
Időkeret: Day1,14,29,56,84,112
|
Day1,14,29,56,84,112
|
|
Number of participants with clinically significant change from baseline in physical examination
Időkeret: Day1,14,29,56,84,112
|
Day1,14,29,56,84,112
|
|
PR Interval
Időkeret: Day14,29,56,84,112
|
Day14,29,56,84,112
|
|
QRS Interval
Időkeret: Day14,29,56,84,112
|
Day14,29,56,84,112
|
|
QT Interval
Időkeret: Day14,29,56,84,112
|
Day14,29,56,84,112
|
|
QTc Interval
Időkeret: Day14,29,56,84,112
|
Day14,29,56,84,112
|
Másodlagos eredményintézkedések
Eredménymérő |
Időkeret |
|---|---|
|
Area Under Curve#0-t#
Időkeret: Day1,2,14,28,29
|
Day1,2,14,28,29
|
|
Area Under the Concentration-time curve from time zero to τ at steady state
Időkeret: Day1,2,14,28,29
|
Day1,2,14,28,29
|
|
Area Under Curve#0-∞#
Időkeret: Day1,2,14,28,29
|
Day1,2,14,28,29
|
|
Maximum Plasma Concentration
Időkeret: Day1,2,14,28,29
|
Day1,2,14,28,29
|
|
Time to Maximum (plasma) Concentration
Időkeret: Day1,2,14,28,29
|
Day1,2,14,28,29
|
|
Elimination Half-Life
Időkeret: Day1,2,14,28,29
|
Day1,2,14,28,29
|
|
CL/F
Időkeret: Day1,2,14,28,29
|
Day1,2,14,28,29
|
|
Apparent Volume of Distribution
Időkeret: Day1,2,14,28,29
|
Day1,2,14,28,29
|
|
Cmin,ss
Időkeret: Day1,2,14,28,29
|
Day1,2,14,28,29
|
|
Cav,ss
Időkeret: Day1,2,14,28,29
|
Day1,2,14,28,29
|
|
Rac_Cmax
Időkeret: Day1,2,14,28,29
|
Day1,2,14,28,29
|
|
Rac_AUC0-tau
Időkeret: Day1,2,14,28,29
|
Day1,2,14,28,29
|
|
DF
Időkeret: Day1,2,14,28,29
|
Day1,2,14,28,29
|
|
MRI-PDFF-determined liver fat content (LFC)
Időkeret: Day29,112
|
Day29,112
|
|
Fibroscan-measured liver stiffness measurement (LSM)
Időkeret: Day29,112
|
Day29,112
|
|
AST/PLT Ratio Index
Időkeret: Day1,14,29,56,112
|
Day1,14,29,56,112
|
|
Triglyceride
Időkeret: Day1,14,29,56,84,112
|
Day1,14,29,56,84,112
|
|
Total Cholesterol
Időkeret: Day1,14,29,56,84,112
|
Day1,14,29,56,84,112
|
|
Low-Density Lipoprotein Cholesterol
Időkeret: Day1,14,29,56,84,112
|
Day1,14,29,56,84,112
|
|
High-Density Lipoprotein Cholesterol
Időkeret: Day1,14,29,56,84,112
|
Day1,14,29,56,84,112
|
|
Apolipoprotein A1
Időkeret: Day1,14,29,56,84,112
|
Day1,14,29,56,84,112
|
|
Apolipoprotein B
Időkeret: Day1,14,29,56,84,112
|
Day1,14,29,56,84,112
|
|
Lipoprotein(a)
Időkeret: Day1,14,29,56,84,112
|
Day1,14,29,56,84,112
|
|
Alanine Aminotransferase
Időkeret: Day1,14,29,56,84,112
|
Day1,14,29,56,84,112
|
|
Aspartate Aminotransferase
Időkeret: Day1,14,29,56,84,112
|
Day1,14,29,56,84,112
|
|
Gamma-Glutamyl Transferase
Időkeret: Day1,14,29,56,84,112
|
Day1,14,29,56,84,112
|
|
body weight
Időkeret: Day1,14,29,56,84,112
|
Day1,14,29,56,84,112
|
|
body Mass Index
Időkeret: Day1,14,29,56,84,112
|
Day1,14,29,56,84,112
|
|
waist circumference
Időkeret: Day1,14,29,56,84,112
|
Day1,14,29,56,84,112
|
|
hip circumference
Időkeret: Day1,14,29,56,84,112
|
Day1,14,29,56,84,112
|
|
Hepatitis B surface antigen
Időkeret: Day1,14,29,56,84,112
|
Day1,14,29,56,84,112
|
|
high-sensitivity C-reactive protein
Időkeret: Day1,2,14,28,29
|
Day1,2,14,28,29
|
|
Tumor necrosis factor-α
Időkeret: Day1,2,14,28,29
|
Day1,2,14,28,29
|
|
Cytokeratin-18 fragment M30
Időkeret: Day1,2,14,28,29
|
Day1,2,14,28,29
|
|
Procollagen type III N-terminal peptide(Pro-C3)
Időkeret: Day1,2,14,28,29
|
Day1,2,14,28,29
|
|
percent change from baseline in Pro-C3
Időkeret: Day1,2,14,28,29
|
Day1,2,14,28,29
|
|
Insulin-like Growth Factors-1
Időkeret: Day1,29
|
Day1,29
|
|
Insulin-like Growth Factor Binding Protein 3 (IGFBP-3)
Időkeret: Day1,29
|
Day1,29
|
|
percent change from baseline in IGFBP-3
Időkeret: Day1,29
|
Day1,29
|
|
FIB-4
Időkeret: Day1,14,29,56,112
|
Day1,14,29,56,112
|
|
Enhanced Liver Fibrosis
Időkeret: Day1,14,29
|
Day1,14,29
|
Együttműködők és nyomozók
Szponzor
Nyomozók
- Kutatásvezető: Jidong Jia, Ph.D, Beijing Friendship Hospital
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Becsült)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
- Vérrel terjedő fertőzések
- Patológiás folyamatok
- Krónikus betegség
- Betegség tulajdonságai
- Fertőzések
- Vírusos betegségek
- Emésztőrendszeri betegségek
- Májbetegségek
- Hepatitis, vírusos, emberi
- Fertőző betegségek
- DNS vírusfertőzések
- Hepadnaviridae fertőzések
- Hepatitis, krónikus
- Májgyulladás
- Kóros állapotok, jelek és tünetek
- Hepatitisz B
- Hepatitis B, krónikus
Egyéb vizsgálati azonosító számok
- ACT500-4/003
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .